Ajanta Pharma Limited (AJANTPHARM.BO)
INR 2491.9
(4.95%)
INR 2491.9
(4.95%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 8.16 Billion INR | 38.81% |
| 2022 | 5.87 Billion INR | -17.5% |
| 2021 | 7.12 Billion INR | 8.99% |
| 2020 | 6.53 Billion INR | 39.81% |
| 2019 | 4.67 Billion INR | 20.86% |
| 2018 | 3.86 Billion INR | -17.43% |
| 2017 | 4.68 Billion INR | -7.54% |
| 2016 | 5.06 Billion INR | 26.26% |
| 2015 | 4.01 Billion INR | 29.55% |
| 2014 | 3.09 Billion INR | 32.49% |
| 2013 | 2.33 Billion INR | 108.62% |
| 2012 | 1.12 Billion INR | 45.1% |
| 2011 | 772.65 Million INR | 52.36% |
| 2010 | 507.12 Million INR | 49.14% |
| 2009 | 340.03 Million INR | 33.71% |
| 2008 | 254.31 Million INR | 16.23% |
| 2007 | 218.8 Million INR | 49.24% |
| 2006 | 146.61 Million INR | 18.75% |
| 2005 | 123.46 Million INR | 25.35% |
| 2004 | 98.49 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 2.16 Billion INR | -11.92% |
| 2024 Q1 | 2.45 Billion INR | 21.24% |
| 2023 Q4 | 2.02 Billion INR | -3.48% |
| 2023 Q1 | 2.08 Billion INR | 70.24% |
| 2023 Q2 | 1.95 Billion INR | -6.16% |
| 2023 FY | 8.16 Billion INR | 38.81% |
| 2023 Q3 | 2.1 Billion INR | 7.54% |
| 2022 Q4 | 1.22 Billion INR | -9.11% |
| 2022 FY | 5.87 Billion INR | -17.5% |
| 2022 Q2 | 1.56 Billion INR | -10.32% |
| 2022 Q3 | 1.34 Billion INR | -14.11% |
| 2022 Q1 | 1.74 Billion INR | 15.48% |
| 2021 FY | 7.12 Billion INR | 8.99% |
| 2021 Q4 | 1.51 Billion INR | -21.15% |
| 2021 Q1 | 1.73 Billion INR | 9.1% |
| 2021 Q3 | 1.91 Billion INR | -2.12% |
| 2021 Q2 | 1.95 Billion INR | 12.77% |
| 2020 Q3 | 1.76 Billion INR | 3.77% |
| 2020 Q4 | 1.59 Billion INR | -9.83% |
| 2020 FY | 6.53 Billion INR | 39.81% |
| 2020 Q1 | 1.47 Billion INR | 14.4% |
| 2020 Q2 | 1.7 Billion INR | 15.2% |
| 2019 Q3 | 1.07 Billion INR | -7.57% |
| 2019 Q2 | 1.16 Billion INR | 1.51% |
| 2019 Q1 | 1.14 Billion INR | 28.96% |
| 2019 FY | 4.67 Billion INR | 20.86% |
| 2019 Q4 | 1.29 Billion INR | 20.09% |
| 2018 FY | 3.86 Billion INR | -17.43% |
| 2018 Q4 | 888.9 Million INR | 32.87% |
| 2018 Q3 | 669 Million INR | -46.65% |
| 2018 Q2 | 1.25 Billion INR | 18.53% |
| 2018 Q1 | 1.05 Billion INR | 11.96% |
| 2017 Q2 | 1.31 Billion INR | 39.14% |
| 2017 Q1 | 947.9 Million INR | -16.87% |
| 2017 FY | 4.68 Billion INR | -7.54% |
| 2017 Q4 | 944.9 Million INR | -35.93% |
| 2017 Q3 | 1.47 Billion INR | 11.81% |
| 2016 Q3 | 1.42 Billion INR | 9.14% |
| 2016 Q2 | 1.3 Billion INR | 9.29% |
| 2016 Q1 | 1.19 Billion INR | 9.72% |
| 2016 FY | 5.06 Billion INR | 26.26% |
| 2016 Q4 | 1.14 Billion INR | -20.04% |
| 2015 Q4 | 1.08 Billion INR | -2.1% |
| 2015 FY | 4.01 Billion INR | 29.55% |
| 2015 Q2 | 999.6 Million INR | 19.23% |
| 2015 Q3 | 1.11 Billion INR | 11.34% |
| 2015 Q1 | 838.4 Million INR | 13.08% |
| 2014 Q1 | 596.6 Million INR | 0.0% |
| 2014 Q4 | 741.4 Million INR | -20.33% |
| 2014 FY | 3.09 Billion INR | 32.49% |
| 2014 Q3 | 930.6 Million INR | 12.12% |
| 2014 Q2 | 830 Million INR | 39.12% |
| 2013 FY | 2.33 Billion INR | 108.62% |
| 2012 Q1 | - INR | 0.0% |
| 2012 FY | 1.12 Billion INR | 45.1% |
| 2012 Q2 | - INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2012 Q4 | - INR | 0.0% |
| 2011 FY | 772.65 Million INR | 52.36% |
| 2010 FY | 507.12 Million INR | 49.14% |
| 2009 FY | 340.03 Million INR | 33.71% |
| 2008 FY | 254.31 Million INR | 16.23% |
| 2007 FY | 218.8 Million INR | 49.24% |
| 2006 FY | 146.61 Million INR | 18.75% |
| 2005 FY | 123.46 Million INR | 25.35% |
| 2004 FY | 98.49 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | -32.534% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 74.277% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | -73.326% |
| Granules India Limited | 4.05 Billion INR | -101.369% |
| Indoco Remedies Limited | 984.6 Million INR | -728.935% |
| Achyut Healthcare Limited | 5.73 Million INR | -142288.346% |
| Alkem Laboratories Limited | 17.95 Billion INR | 54.55% |
| Alpa Laboratories Limited | 167.76 Million INR | -4764.96% |
| Brooks Laboratories Limited | -195.91 Million INR | 4265.854% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | -405.337% |
| Bajaj HealthCare Limited | -837.93 Million INR | 1074.03% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -981.677% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 85.343% |
| Eris Lifesciences Limited | 3.91 Billion INR | -108.216% |
| FDC Limited | 3.05 Billion INR | -167.401% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 154.351% |
| Gufic Biosciences Limited | 861.35 Million INR | -847.541% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | -93.882% |
| Ipca Laboratories Limited | 5.47 Billion INR | -49.113% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -3533.397% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 4237.031% |
| Lasa Supergenerics Limited | -217.3 Million INR | 3855.856% |
| Laurus Labs Limited | 1.6 Billion INR | -408.359% |
| Lupin Limited | 19.14 Billion INR | 57.369% |
| Mankind Pharma Limited | 19.12 Billion INR | 57.333% |
| Medicamen Biotech Limited | 109.31 Million INR | -7366.563% |
| Medico Remedies Limited | 82.9 Million INR | -9744.166% |
| Megasoft Limited | -127.46 Million INR | 6503.041% |
| NATCO Pharma Limited | 13.88 Billion INR | 41.211% |
| Piramal Pharma Limited | 178.2 Million INR | -4480.079% |
| RPG Life Sciences Limited | 876.6 Million INR | -831.063% |
| Sigachi Industries Limited | 571.8 Million INR | -1327.365% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 91.477% |
| Suven Pharmaceuticals Limited | 3 Billion INR | -171.803% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -3124.159% |
| Unichem Laboratories Limited | -704.74 Million INR | 1258.11% |
| Wanbury Limited | 559.56 Million INR | -1358.585% |
| Windlas Biotech Limited | 581.87 Million INR | -1302.667% |
| ZIM Laboratories Limited | 172.46 Million INR | -4632.408% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 78.853% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 310.78% |
| Divi's Laboratories Limited | 16 Billion INR | 48.989% |
| Hester Biosciences Limited | 188.89 Million INR | -4220.875% |
| Procter & Gamble Health Limited | 2 Billion INR | -306.095% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -1714.816% |
| Bal Pharma Limited | 73.92 Million INR | -10940.962% |
| Strides Pharma Science Limited | -706.14 Million INR | 1255.819% |
| Venus Remedies Limited | 284.9 Million INR | -2764.679% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | -276.285% |
| Nectar Lifesciences Limited | 49.95 Million INR | -16239.74% |
| Shilpa Medicare Limited | 318.74 Million INR | -2460.598% |
| Aarti Drugs Limited | 1.71 Billion INR | -376.128% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | -507.134% |
| Suven Life Sciences Limited | -1.05 Billion INR | 876.74% |
| Ind-Swift Limited | 142.31 Million INR | -5635.035% |
| Valiant Laboratories Limited | 3.19 Million INR | -255272.34% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | -47.689% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 243.846% |
| Themis Medicare Limited | 435.23 Million INR | -1775.227% |
| Hikal Limited | 696.02 Million INR | -1072.624% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 50.726% |
| Sequent Scientific Limited | -358.69 Million INR | 2375.419% |
| Novartis India Limited | 851.9 Million INR | -858.058% |
| Wockhardt Limited | -4.63 Billion INR | 276.279% |
| Jubilant Pharmova Limited | 771 Million INR | -958.586% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -114983.192% |
| Neuland Laboratories Limited | 3 Billion INR | -171.985% |
| Morepen Laboratories Limited | 961.59 Million INR | -748.763% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -5489.669% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 9096.88% |